Why Is Brain Cancer Focused TransCode Therapeutics Stock Trading 300% Higher Today?

TransCode Therapeutics Inc RNAZ shares are trading higher after the company announced results with its lead therapeutic candidate, TTX-MC138, in murine models bearing human glioblastoma multiforme (GBM) tumors. 

In this study, the therapeutic candidate was delivered to brain tumors and effectively engaged its target.

In the study reported by TransCode, mice implanted with tumors derived from human GBM patients were treated with TTX-MC138 and imaged by magnetic resonance imaging (MRI) to determine the delivery of the therapeutic candidate to the tumors. 

In addition, the pharmacodynamic activity of TTX-MC138 was determined by measuring the inhibition of the therapeutic target, miRNA-10b.

TTX-MC138 was injected intravenously and accumulated efficiently in the tumors. 

The therapeutic candidate showed lasting activity and significantly inhibited miRNA-10b, a driver of tumor progression in glioblastoma.

MiRNA-10b is described as the master regulator of cancer progression in several advanced solid tumors. 

TransCode says that TTX-MC138 could be used to treat many of these cancers. 

Administration of TTX-MC138 has resulted in complete regression of metastatic disease in numerous mouse models of pancreatic and breast cancer. In addition, TTX-MC138 was successfully delivered and demonstrated efficacy in spontaneous feline mammary carcinoma.

TransCode's first-in-human clinical trial with TTX-MC138 is open for enrollment and has dosed its first patient.

In this clinical trial, up to 12 patients will be given a single microdose of radiolabeled TTX-MC138 followed by noninvasive PET-MRI and other testing. 

Price Action: RNAZ shares are up 350.30% at $2.99 on the last check Monday.